Meeting
2023 ASCO Annual Meeting
Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC).
Authors
Dejan Juric
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA
Dejan Juric , Debra L. Richardson , Babar Bashir , Manish Sharma , Kyriakos P. Papadopoulos , Sara Mathews , Graeme Hodgson , Susan Henry , Sofia Paul , Terence Hall , David A. Roth , Michael Kelly , Tanya Abdul Malak , Virginia Klimek
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT04247126
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3081)
DOI
10.1200/JCO.2023.41.16_suppl.3081
Abstract #
3081
Poster Bd #
279
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
G1T38, an oral CDK4/6 inhibitor, dosed continuously in combination with fulvestrant for HR+ breast cancer: Preliminary phase 1b results.
First Author: Iurie Bulat
Poster
2023 ASCO Annual Meeting
A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).
First Author: Sara A. Hurvitz
Poster
2023 ASCO Annual Meeting
First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy.
First Author: Timothy A. Yap
Poster
2023 ASCO Annual Meeting
A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor–positive (ER+)/HER2-negative (HER2-) breast cancer.
First Author: Virginia F. Borges